Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 57.

Happold, C; Gorlia, T; Chinot, O; Gilbert, M R; Nabors, L B; Wick, W; Pugh, S L; Hegi, M; Cloughesy, T; Roth, P; Reardon, D A; Perry, J R; Mehta, M P; Stupp, R; Weller, M (2016). Reply to F. Felix et al and M.F. Fay et al. Journal of Clinical Oncology, 34(25):3107-3108.

Pitter, K L; Tamagno, I; Alikhanyan, K; Hosni-Ahmed, A; Pattwell, S S; Donnola, S; Dai, C; Ozawa, T; Chang, M; Chan, T A; Beal, K; Bishop, A J; Barker, C A; Jones, T S; Hentschel, B; Gorlia, T; Schlegel, U; Stupp, R; Weller, M; Holland, E C; Hambardzumyan, D (2016). Corticosteroids compromise survival in glioblastoma. Brain, 139(Pt 5):1458-1471.

Gulden-Sala, W; Roth, P; Brown, M; Andratschke, N; Weller, M; Stupp, R (2016). Gliome – was ich wissen muss in zehn Fragen. Praxis, 105(6):330-337.

Happold, C; Gorlia, T; Chinot, O; Gilbert, M R; Nabors, L B; Wick, W; Pugh, S L; Hegi, M; Cloughesy, T; Roth, P; Reardon, D A; Perry, J R; Mehta, M P; Stupp, R; Weller, M (2016). Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 34(7):731-739.

Weller, Michael; Tabatabai, G; Kästner, B; Felsberg, J; Steinbach, J P; Wick, A; Schnell, O; Hau, P; Herrlinger, U; Sabel, M C; Wirsching, H G; Ketter, R; Bähr, O; Platten, M; Tonn, J C; Schlegel, U; Marosi, C; Goldbrunner, R; Stupp, R; Homicsko, K; Pichler, J; Nikkhah, G; Meixensberger, J; Vajkoczy, P; Kollias, S; Hüsing, J; Reifenberger, G; Wick, W (2015). MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 21(9):2057-2064.

Samaras, P; Pfrommer, S; Seifert, B; Petrausch, U; Mischo, A; Schmidt, A; Schanz, U; Nair, G; Bargetzi, M; Taverna, C; Stupp, R; Stenner-Liewen, F; Renner, C (2015). Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma. Biology of Blood and Marrow Transplantation, 21(1):74-80.

Kurscheid, S; Bady, P; Sciuscio, D; Samarzija, I; Shay, T; Vassallo, I; Criekinge, W V; Daniel, R T; van den Bent, M J; Marosi, C; Weller, M; Mason, W P; Domany, E; Stupp, R; Delorenzi, M; Hegi, M E (2015). Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. Genome Biology, 16(1):16.

Stupp, R; Weller, M (2015). Neuro-Onkologie – eine junge und interdisziplinäre Spezialität. info@onkologie, 5(1):1.

Stupp, R; Picard, M; Weller, M (2014). Does cilengitide deserve another chance?-Authors' reply. Lancet Oncology, 15(13):e585-e586.

Weller, M; van den Bent, M; Hopkins, K; Tonn, J C; Stupp, R; Falini, A; Cohen-Jonathan-Moyal, E; Frappaz, D; Henriksson, R; Balana, C; Chinot, O; Ram, Z; Reifenberger, G; Soffietti, R; Wick, W (2014). EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncology, 15(9):e395-e403.

Dunet, V; Maeder, P; Nicod-Lalonde, M; Lhermitte, B; Pollo, C; Bloch, J; Stupp, R; Meuli, R; Prior, O J (2014). Combination of MRI and dynamic FET PET for initial glioma grading. Nuklearmedizin. Nuclear medicine, 53(4):155-161.

Stupp, R; Weller, M (2014). Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. Neuro-Oncology, 16(6):765-767.

Stupp, R; Hegi, M E; Gorlia, T; et al; Kim, C Y; Nabors, L B; Reardon, D A; van den Bent, M J; Hicking, C; Markivskyy, A; Picard, M; Weller, M (2014). Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, 15(10):1100-1108.

Eisele, G; Wick, A; Eisele, A C; Clément, P M; Tonn, J; Tabatabai, G; Ochsenbein, A; Schlegel, U; Neyns, B; Krex, D; Simon, M; Nikkhah, G; Picard, M; Stupp, R; Wick, W; Weller, M (2014). Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. Journal of Neuro-Oncology, 117(1):141-145.

Hundsberger, T; Tonder, M; Hottinger, A; Brügge, D; Roelcke, U; Putora, P M; Stupp, R; Weller, M (2014). Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients. Journal of Neuro-Oncology, 118(2):321-328.

Rossetti, A O; Jeckelmann, S; Novy, J; Roth, P; Weller, M; Stupp, R (2014). Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. Neuro-Oncology, 16(4):584-588.

Roth, P; Stupp, R; Eisele, G; Weller, M (2014). Treatment of primary CNS lymphoma. Current Treatment Options in Neurology, 16(1):277.

Stupp, R; Hottinger, A; Hegi, M E; Weller, M (2013). Diagnostik und Therapie von Gliomen. Swiss Medical Forum, 13(22):421-426.

Weller, M; Stupp, R; Wick, W (2013). Drei negative (?)Phase-III-Studien auf dem ASCO-Kongress 2013. Steht die Angiogenesehemmung beim Glioblastom vor dem Aus? Leading Opinions Hämatologie & Onkologie, 4:52-53.

Weller, M; Stupp, R (2013). EORTC-EANO-ESMO-Konferenz 2013: die vIII-Mutationsvariante des epidermalen Wachstumsfaktorrezeptors – EGFRvIII als Angriffspunkt für die Immuntherapie des Glioblastoms. Leading Opinions Hämatologie & Onkologie:52-53.

Bady, P; Sciuscio, D; Diserens, A C; Bloch, J; van den Bent, M J; Marosi, C; Dietrich, P Y; Weller, M; Mariani, L; Heppner, F L; Macdonald, D R; Lacombe, D; Stupp, R; Delorenzi, M; Hegi, M E (2013). Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 126(1):159.

Weller, M; Pfister, S M; Wick, W; Hegi, M E; Reifenberger, G; Stupp, R (2013). Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncology, 14(9):e370-e379.

Laperriere, N; Weller, M; Stupp, R; Perry, J R; Brandes, A A; Wick, W; van den Bent, M J (2013). Optimal management of elderly patients with glioblastoma. Cancer Treatment Reviews, 39(4):350-357.

Brandes, A A; Franceschi, E; Gorlia, T; Wick, W; Jacobs, A H; Baumert, B G; van den Bent, M; Weller, M; Stupp, R (2012). Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. European Journal of Cancer, 48(6):896-903.

Tabatabai, G; Hegi, M; Stupp, R; Weller, M (2012). Clinical implications of molecular neuropathology and biomarkers for malignant glioma. Current Neurology and Neuroscience Reports, 12(3):302-307.

Weller, M; Stupp, R; Wick, W (2012). Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncology, 13(9):e375-e382.

Weller, M; Stupp, R; Hegi, M; Wick, W (2012). Individualized targeted therapy for glioblastoma: fact or fiction? Cancer Journal, 18(1):40-44.

Bady, P; Sciuscio, D; Diserens, A C; Bloch, J; van den Bent, M J; Marosi, C; Dietrich, P Y; Weller, M; Mariani, L; Heppner, F L; McDonald, D R; Lacombe, D; Stupp, R; Delorenzi, M; Hegi, M E (2012). MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 124(4):547-560.

Weller, M; Stupp, R; Hegi, M E; van den Bent, M; Tonn, J C; Sanson, M; Wick, W; Reifenberger, G (2012). Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro-Oncology, 14(Suppl. 4):iv100-iv108.

Hegi, M E; Janzer, R C; Lambiv, W L; Gorlia, T; Kouwenhoven, M C M; Hartmann, C; von Deimling, A; Martinet, D; Besuchet Schmutz, N; Diserens, A C; Hamou, M F; Bady, P; Weller, M; van den Bent, M J; Mason, W P; Mirimanoff, R O; Stupp, R; Mokhtari, K; Wesseling, P (2012). Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathologica, 123(6):841-852.

Weller, M; Stupp, R (2012). Prime time for molecular marker diagnostics in neuro-oncology. Current Opinion in Neurology, 25(6):743-744.

Reardon, D A; Neyns, B; Weller, M; Tonn, J C; Nabors, L B; Stupp, R (2011). Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncology, 7(3):339-354.

Weller, M; Stupp, R (2011). Clinical trials in neuro-oncology: one step forward, two steps back? Current Opinion in Neurology, 24(6):597-598.

Preusser, M; de Ribaupierre, S; Wöhrer, A; Erridge, S C; Hegi, M; Weller, M; Stupp, R (2011). Current concepts and management of glioblastoma. Annals of Neurology, 70(1):9-21.

Weller, M; Gorlia, T; Cairncross, J G; van den Bent, M J; Mason, W; Belanger, K; Brandes, A A; Bogdahn, U; Macdonald, D R; Forsyth, P; Rossetti, A O; Lacombe, D; Mirimanoff, R-O; Vecht, C J; Stupp, R (2011). Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology, 77(12):1156-1164.

Tabatabai, G; Tonn, J C; Stupp, R; Weller, M (2011). The role of integrins in glioma biology and anti-glioma therapies. Current Pharmaceutical Design, 17(23):2402-2410.

Wick, W; Weller, M; van den Bent, M; Stupp, R (2010). Bevacizumab and recurrent malignant gliomas: a European perspective. Journal of Clinical Oncology, 28(12):e188-e189; author reply e190.

Stupp, R; Weller, M (2010). 2010: neuro-oncology is moving! Current Opinion in Neurology, 23(6):553-555.

Tabatabai, G; Stupp, R (2010). Angiogenesehemmung in der Neuroonkologie: Eine vielversprechende Therapiestrategie gegen maligne Gliome. Der Nervenarzt, 81(8):936-939.

Martinelli, G; Schmitz, S F H; Utiger, U; Cerny, T; Hess, U; Bassi, S; Okkinga, E; Stupp, R; Stahel, R; Heizmann, M; Vorobiof, D; Lohri, A; Dietrich, P Y; Zucca, E; Ghielmini, M (2010). Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. Journal of Clinical Oncology, 28(29):4480-4484.

Weller, M; Stupp, R; Reifenberger, G; Brandes, A A; van den Bent, M J; Wick, W; Hegi, M E (2010). MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Reviews. Neurology, 6(1):39-51.

Tabatabai, G; Stupp, R; van den Bent, M J; Hegi, M E; Tonn, J C; Wick, W; Weller, M (2010). Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathologica, 120(5):585-592.

Stupp, R; Hegi, M; Weller, M (2010). Neuro-oncology, a decade of temozolomide and beyond. Expert Review of Anticancer Therapy, 10(11):1675-1677.

Stupp, R; Hegi, M E; Neyns, B; Goldbrunner, R; Schlegel, U; Clement, P M; Grabenbauer, G G; Ochsenbein, A F; Simon, M; Dietrich, P Y; Pietsch, T; Hicking, C; Tonn, J C; Diserens, A C; Pica, A; Hermisson, M; Krueger, S; Picard, M; Weller, M (2010). Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology, 28(16):2712-2718.

Stupp, R; Hegi, M E; Neyns, B; Goldbrunner, R; Schlegel, U; Clement, P M J; Grabenbauer, G G; Ochsenbein, A F; Simon, M; Dietrich, P Y; Pietsch, T; Hicking, C; Tonn, J C; Diserens, A C; Pica, A; Hermisson, M; Krueger, S; Picard, M; Weller, M (2010). Reply to M.C. Chamberlain. Journal of Clinical Oncology, 28(33):e696-e697.

Weller, M; Wick, W; Hegi, M E; Stupp, R; Tabatabai, G (2010). Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? Future Oncology, 6(9):1407-1414.

Tabatabai, G; Weller, M; Nabors, B; Picard, M; Reardon, D; Mikkelsen, T; Ruegg, C; Stupp, R (2010). Targeting integrins in malignant glioma. Targeted Oncology, 5(3):175-181.

Weller, M; Stupp, R (2009). Approval of new drugs for glioblastoma. Current Opinion in Neurology, 22(6):617-618.

Stupp, R; Mayer, M; Kann, R; Weder, W; Zouhair, A; Betticher, D C; Roth, A D; Stahel, R A; Majno, S; Peters, S; Jost, L; Furrer, M; Thierstein, S; Schmid, R A; Hsu-Schmitz, S F; Mirimanoff, R O; Ris, H B; Pless, M (2009). Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncology, 10(8):785-793.

Maurer, G D; Tritschler, I; Adams, B; Tabatabai, G; Wick, W; Stupp, R; Weller, M (2009). Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro-Oncology, 11(6):747-756.

Stupp, R; Hegi, M E; Mason, W P; van den Bent, M J; Taphoorn, M J B; Janzer, R C; Ludwin, S K; Allgeier, A; Fisher, B; Belanger, K; Hau, P; Brandes, A A; Gijtenbeek, J; Marosi, C; Vecht, C J; Mokhtari, K; Wesseling, P; Villa, S; Eisenhauer, E; Gorlia, T; Weller, M; Lacombe, D; Cairncross, J G; Mirimanoff, R O (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, 10(5):459-466.

Tabatabai, G; Stupp, R (2009). Primetime for antiangiogenic therapy. Current Opinion in Neurology, 22(6):639-644.

Weller, M; Reardon, D; Nabors, B; Stupp, R (2009). Will integrin inhibitors have proangiogenic effects in the clinic? Nature Medicine, 15(7):726; author reply 727.

Ribi, K; Bernhard, J; Schuller, J C; Weder, W; Bodis, S; Jörger, M; Betticher, D; Schmid, R A; Stupp, R; Ris, H B; Stahel, R A (2008). Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung Cancer, 61(3):398-404.

Hegi, M E; Liu, L; Herman, J G; Stupp, R; Wick, W; Weller, M; Mehta, M P; Gilbert, M R (2008). Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. Journal of Clinical Oncology, 26(25):4189-4199.

D'Addario, G; Rauch, D; Stupp, R; Pless, M; Stahel, R; Mach, N; Jost, L; Widmer, L; Tapia, C; Bihl, M; Mayer, M; Ribi, K; Lerch, S; Bubendorf, L; Betticher, D C (2008). Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Annals of Oncology, 19(4):739-745.

Gorlia, T; van den Bent, M J; Hegi, M E; Mirimanoff, R O; Weller, M; Cairncross, J G; Eisenhauer, E; Belanger, K; Brandes, A A; Allgeier, A; Lacombe, D; Stupp, R (2008). Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncology, 9(1):29-38.

This list was generated on Tue Oct 17 14:10:44 2017 CEST.